Inspired by Nature.
Empowered by Technology.
Committed to Life.
Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
EliChip® R&D Feasibility & Assay Migration Service
Microfluidic assay migration for field-oriented research and translational applications
NAMina Bio offers an R&D feasibility and translational assay-migration service to help research teams, biotech companies, diagnostic innovators, agrifood groups, and veterinary-health teams evaluate whether existing ELISA or immunoassay workflows can be adapted into the EliChip® microfluidic cartridge format.
The EliChip® platform, developed by Trustech Diagnostics and commercially supported by Auralis Biotech, is designed to convert established assay chemistries into compact, low-volume, digitally read microfluidic formats for field-oriented and decentralized applications.
NAMina Bio positions this capability as an R&D service layer, helping partners assess technical feasibility, assay-migration strategy, biological use case, pilot-study design, and translational development pathway.
What this service helps you evaluate
Many promising assays remain locked inside traditional laboratory workflows. Conventional ELISA methods can be quantitative and sensitive, but they often require centralized laboratories, larger sample volumes, trained personnel, and longer turnaround times.
Through this R&D service, NAMina Bio helps evaluate whether a selected assay, biomarker workflow, reagent system, or biological target can be adapted toward a microfluidic format suitable for more agile, field-oriented, or decentralized testing applications.
This may include:
Assay feasibility review
Assessment of whether your existing ELISA, immunoassay, biomarker panel, reagent system, or biological target is technically suitable for EliChip®-style migration.
Reagent and workflow mapping
Review of antibodies, standards, buffers, sample type, detection chemistry, matrix complexity, and workflow constraints.
Microfluidic migration strategy
Definition of the technical steps required to move from a conventional plate-based or tube-based assay into a cartridge-compatible workflow.
Pilot validation design
Support in designing early R&D studies to compare performance, sensitivity, reproducibility, sample volume,and time-to-result against the original assay format.
Application positioning
Identification of the strongest use case for translational research, field testing, animal health, agrifood,environmental monitoring, or decentralized biological testing.
How the R&D service works
1. Feasibility intake
NAMina reviews the biological target, assay format, reagent system, sample matrix, intended use case, and performance expectations.
2. Technical fit assessment
We evaluate whether the assay concept is a reasonable candidate for microfluidic migration, considering sample volume, detection chemistry, sensitivity needs, matrix interference, and workflow complexity.
3. Pilot study design
If the assay is suitable, NAMina Bio helps design a pilot plan to compare the original workflow with the migrated microfluidic format.
4. Partner coordination
NAMina Bio supports structured coordination with the relevant technology partners, including Auralis Biotech and Trustech Diagnostics, where appropriate.
5. R&D interpretation
The output is an R&D feasibility package summarizing technical readiness, development risks, next steps, and potential application positioning.
What you receive
Depending on the project scope, deliverables may include:
-
Assay feasibility assessment
-
Reagent and workflow review
-
Sample matrix and use-case analysis
-
Microfluidic migration roadmap
-
Pilot study design
-
Partner coordination plan
-
Early technical-risk summary
-
Translational application positioning
-
R&D feasibility report
Important Note
This service is intended for research, feasibility, and early development purposes. It does not constitute clinical diagnostic validation, regulatory clearance, or commercial product approval. Each project requires a separate technical review and, where appropriate, a dedicated SOW, NDA, and partner agreement before confidential information, biological samples, reagents, or proprietary assay materials are exchanged.
Explore EliChip® Assay Migration
Have an ELISA, immunoassay, biomarker workflow, or reagent system that could benefit from a faster, lower-volume, field-oriented format?
NAMina Bio can help you assess whether your assay is a candidate for microfluidic migration and design the first R&D feasibility path.
